XML 67 R39.htm IDEA: XBRL DOCUMENT v3.20.1
Research, Collaboration and Licensing Agreements - Additional Information - Strategic Partnership Revenue (Detail) - USD ($)
1 Months Ended 3 Months Ended
Mar. 31, 2020
Jan. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue     $ 8,269,000 $ 11,925,000  
Contract assets $ 0   0   $ 0
Performance obligation recognized     0 3,530,000  
Bei Gene          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred revenue 32,941,000   32,941,000   $ 32,941,000
Bei Gene | Milestone revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue $ 5,000,000   5,000,000 0  
Eli Lilly and Company | Milestone revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue   $ 8,000,000 $ 0 $ 8,000,000